Biomarin Pharmaceutical (NASDAQ: BMRN) — Company Overview, News & Financial Data
BioMarin Pharmaceutical develops therapies for rare genetic diseases, aiming to improve health outcomes for patients.
Biomarin Pharmaceutical
Biomarin Pharmaceutical is a global biotechnology company focused on developing and commercializing targeted therapies for people living with serious and life-threatening rare genetic conditions. Founded in 1997, the company develops enzyme replacement therapies and genetic medicines aimed at addressing the root causes of metabolic, skeletal, and neurological disorders. Its commercial portfolio includes biopharmaceutical products for conditions such as achondroplasia, mucopolysaccharidosis disorders, phenylketonuria, and severe hemophilia A. BioMarin conducts research, clinical development, biomanufacturing, and global commercialization activities across multiple international markets to support patients and healthcare systems.
Snapshot
Operations
Products and/or services of Biomarin Pharmaceutical
- Skeletal Condition Therapies: Prescription biopharmaceutical treatments indicated to increase linear growth in pediatric patients with achondroplasia with open growth plates, administered through daily subcutaneous injections and distributed across hospital networks in North America, Europe, and Asia-Pacific.
- Lysosomal Storage Disease Treatments: Recombinant enzyme replacement therapies manufactured at dedicated biologic production plants to manage progressive genetic conditions including mucopolysaccharidosis types IVA, VI, and I, supplied directly to medical institutions across international health jurisdictions.
- Phenylketonuria Management Products: Prescription enzyme substitution therapies and oral formulations engineered to lower blood phenylalanine levels in adult and pediatric patients, distributed globally through specialized biopharmaceutical distribution channels and healthcare provider networks.
- Hemophilia Gene Therapies: Adeno-associated virus vector-based gene therapy candidates and commercial formulations engineered for severe hemophilia A treatment, administered via single-dose intravenous infusions to restore endogenous coagulation factor VIII production in adult patients.
- Investigational Clinical Pipeline: Clinical-stage research and development programs advancing targeted molecular therapies, oligonucleotide candidates, and enzyme replacement platforms to address unserved rare pediatric, cardiovascular, and metabolic disorders through phase two and three clinical trials.
- Biopharmaceutical Manufacturing Operations: Large-scale biologic drug substance and drug product manufacturing facilities operating cell culture, protein purification, sterile filling, packaging, and quality control systems across specialized production sites in California and Ireland.
Biomarin Pharmaceutical executive team
- Alexander HardyPresident, CEO & Director
- Brian R. MuellerCFO & Executive VP of Finance
- C. Greg GuyerExecutive VP & CTO
- Cristin HubbardExecutive VP & Chief Commercial Officer
- Gregory FribergExecutive VP and Chief Research & Development Officer
- Rashmi Eshwar RamchandaniVP, Chief Accounting Officer & Principal Accounting Officer
- Kevin EgganChief Scientific Officer & Senior VP of Research and Early Development
- Arpit DaveExecutive Vice President, Chief Digital & Information Officer
- George Eric DavisExecutive VP, Chief Legal Officer & Secretary
- Cara BauerExecutive VP & Chief People Officer
Latest news about Biomarin Pharmaceutical
Key financials
Reported results for Biomarin Pharmaceutical, in USD.
- Market cap
- 10.8B
- Revenue (TTM)
- 3.4B
- P/E ratio
- 151.4
- EPS (diluted, TTM)
- 0.4
- Dividend yield
- —
- Profit margin
- 2.1%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 3.2B | 533.5M | 348.9M | |
| 2.9B | 484.2M | 426.9M | |
| 2.4B | 185.8M | 167.6M | |
| 2.1B | 161M | 141.6M |